anti-Katze C-MYC Antikörper für ELISA

Recommended C-MYC Antibody (geliefert von: Anmelden zum Anzeigen )

Antigen
V-Myc Myelocytomatosis Viral Oncogene Homolog (Avian) (MYC) Antikörper
  • MRTL
  • MYCC
  • bHLHe39
  • c-Myc
  • CMYC
  • c-myc
  • C-MYC
  • LOC100136746
  • RNCMYC
  • mMyc
  • AU016757
  • Myc2
  • Niard
  • Nird
  • MYC
  • cmyc
  • zc-myc
  • c-myc II
  • myc-B
  • myc2
  • CMyc
  • CG10798
  • D-Myc
  • DM
  • DMYc
  • Dm
  • Dmel\CG10798
  • Dmyc
  • EG:BACN5I9.1
  • anon-WO03040301.171
  • bHLHe57
  • c-MYC
  • d-myc
  • dMYC
  • dMyc
  • dMyc1
  • da
  • dm
  • dm/dMyc
  • dm/myc
  • dmyc
  • dmyc1
  • l(1)G0139
  • l(1)G0354
  • l(1)G0359
  • myc
  • MYC proto-oncogene, bHLH transcription factor
  • v-myc myelocytomatosis viral oncogene homolog
  • myelocytomatosis oncogene
  • MYC proto-oncogene, bHLH transcription factor a
  • MYC proto-oncogene, bHLH transcription factor L homeolog
  • v-myc myelocytomatosis viral oncogene homolog (avian)
  • CG10798 gene product from transcript CG10798-RB
  • MYC
  • LOC100136746
  • Myc
  • myca
  • myc.L
Epitop
AA 200-250, N-Term
246
181
76
39
38
36
36
26
22
15
15
15
14
10
10
10
9
5
5
4
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reaktivität
Katze, Human, Affe
859
238
140
48
48
45
40
36
20
19
19
15
14
14
13
9
9
8
6
5
5
4
3
3
2
1
1
1
1
1
Wirt
Kaninchen
487
395
30
17
8
1
Klonalität
Polyklonal
Konjugat
Dieser C-MYC Antikörper ist unkonjugiert
51
48
48
28
25
19
17
17
17
14
13
13
13
13
13
13
12
12
9
9
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
2
1
1
1
1
Applikation
Immunoprecipitation (IP), ELISA, Western Blotting (WB)
537
346
336
251
236
225
155
130
94
63
52
18
16
14
14
10
6
6
3
2
2
1
Hersteller
Anmelden zum Anzeigen
Hersteller Produkt- Nr.
Anmelden zum Anzeigen
Request

Produkt kostenlos erhalten?

Für Ihre Validierungsdaten erstatten wir Ihnen den vollen Kaufpreis. Ich möchte dieses Produkt validieren

Mehr erfahren

Produktnummer ABIN2747734
$ 462.69
Zzgl. Versandkosten $45.00
Relevance Score ABIN Application Konjugat Host Isotype Epitope Hersteller Clonality References Details
1 ABIN2749440 IP ELISA WB FITC Rabbit IgG AA 200-250, N-Term Anmelden zum Anzeigen Polyclonal 0
1 ABIN2749441 IP ELISA WB FITC Rabbit IgG AA 400-454, C-Term Anmelden zum Anzeigen Polyclonal 0
1 ABIN2749439 IP ELISA WB Rabbit IgG AA 400-454, C-Term Anmelden zum Anzeigen Polyclonal 0
1 ABIN5558216 ELISA IP WB Biotin Rabbit N-Term Anmelden zum Anzeigen Polyclonal 0
1 ABIN5558217 ELISA IP WB Biotin Rabbit C-Term Anmelden zum Anzeigen Polyclonal 0

General

Antigen V-Myc Myelocytomatosis Viral Oncogene Homolog (Avian) (MYC) Antikörper
Epitop AA 200-250, N-Term
(246), (181), (76), (39), (38), (36), (36), (26), (22), (15), (15), (15), (14), (10), (10), (10), (9), (5), (5), (4), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reaktivität Katze, Human, Affe
(859), (238), (140), (48), (48), (45), (40), (36), (20), (19), (19), (15), (14), (14), (13), (9), (9), (8), (6), (5), (5), (4), (3), (3), (2), (1), (1), (1), (1), (1)
Wirt Kaninchen
(487), (395), (30), (17), (8), (1)
Klonalität
Polyklonal
Konjugat Dieser C-MYC Antikörper ist unkonjugiert
(51), (48), (48), (28), (25), (19), (17), (17), (17), (14), (13), (13), (13), (13), (13), (13), (12), (12), (9), (9), (5), (5), (5), (5), (5), (5), (5), (5), (5), (5), (5), (5), (5), (5), (5), (5), (4), (4), (4), (4), (4), (4), (4), (4), (4), (4), (4), (4), (4), (4), (4), (4), (4), (2), (1), (1), (1), (1)
Applikation Immunoprecipitation (IP), ELISA, Western Blotting (WB)
(537), (346), (336), (251), (236), (225), (155), (130), (94), (63), (52), (18), (16), (14), (14), (10), (6), (6), (3), (2), (2), (1)
Hersteller Anmelden zum Anzeigen

Produktdetails anti-C-MYC Antikörper

Target Details C-MYC Anwendungsinformationen Handhabung Bilder
Blocking Peptide Zu diesem Produkt passt das Blocking Peptide ABIN2749442.
Kreuzreaktivität Ratte (Rattus), Maus
Kreuzreaktivität (Details) The antibody does not cross react to any other cellular protein.
Produktmerkmale cMyc selective antibodies were generated against a peptide taken from the human protein. The cMyc-selective antibodies are affinity purified on an immobilized antigen based affinity matrix, the isolated antibodies were then stabilized in antibody stabilization buffer for long-term storage. The cMyc-selective antibodies are fully characterized for applications in western blotting and ELISA at the recommended dilutions. The supplier provides cMyc Western blot positive control samples in SDS-PAGE sample buffer.
Reinigung Affinity Purified
Immunogen Synthetic peptide taken within amino acid region 200-250 on human cMyc protein.
Isotyp IgG
Plasmids, Primers & others

Target Details C-MYC

Produktdetails anti-C-MYC Antikörper Anwendungsinformationen Handhabung Bilder zurück nach oben
Antigen
Andere Bezeichnung C-Myc (MYC Antibody Abstract)
Hintergrund Myc genes are a family of proto-oncogenes (L- Myc, N- Myc and C- Myc) which are transcription factors implicated in cellular proliferation, cellular transformation, differentiation, apoptosis, metabolism, adhesion and self-renovation of tumor stem cells. Myc protein acts as transcriptional activator/repressor, and is activated via response to diverse mitogenic signals (including Wnt, Shh and EGF). These proteins share a common basic-helix-loop-helix leucine zipper (bHLH-ZIP) motif required for dimerization and DNA-binding. Myc proteins are nuclear proteins with relatively short half-lives and play a central role as both a key target and a cooperating transcription factor to drive oncogenic growth and is up-regulated in several types of cancers. The cMyc protein is a 55 kDa nuclear factor ubiquitously expressed in the nucleus and is the prototype for oncogene activation by chromosomal translocation. Mutations, overexpression, rearrangement and translocation of this gene are associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt's lymphoma. In Burkitt's lymphomas, the removal or specific mutation of exon 1 in cMyc translocations correlates with suppression of synthesis of the larger protein, and thus contributes to the oncogenic activation of c-myc. cMyc activates the transcription of growth-related genes and its overexpression induces cell-cycle progression thereby implicating in a variety of cancers. Amplification of the c-Myc gene is found in several types of human tumors including lung, breast and colon carcinoma. C-Myc is modified by glycosylation and phosphorylation, and interacts with a number of proteins including SMAD2, SMAD3, Pam, cdc6, BRCA1, Mlh1, p34cdc2, MAD, and Sp1. cMyc is extremely labile and is degraded very quickly even in extracts prepared with boiling SDS sample buffer. c-Myc participates in gene transcription regulation and binds DNA in a non-specific manner, specifically recognizing core sequence 5'-CAC[GA]TG-3'. The gene for cMyc is present on chromosome 8q24.21.
NCBI Accession NP_002458
UniProt P01106
Pathways p53 Signalweg, Zellzyklus, Sensory Perception of Sound, Transition Metal Ion Homeostasis, Mitotic G1-G1/S Phases, Positive Regulation of Endopeptidase Activity, Regulation of Carbohydrate Metabolic Process, Positive Regulation of Response to DNA Damage Stimulus

Anwendungsinformationen

Produktdetails anti-C-MYC Antikörper Target Details C-MYC Handhabung Bilder zurück nach oben
Applikations-hinweise Antibodies were tested in ELISA and western blotting applications at 1:500 dilution using ABIN1686561 samples. Antibody dilutions for these antibodies are for reference only, investigators are expected to determine the optimal conditions. Application of this antibody in other protocols has not yet tested.
WB: > 1:500
IMM & IP pull-down assays: n.d.
IHC: n.d.
Investigators using this antibody in protocols other than listed above can request a complimentary sample of this antibody. n.d. not necessarily means the antibody is not suitable for that application, it simply means we have not yet characterized the antibody for that application.
The antibody labels a strong band of cMyc at 55 kDa in ABIN1686561 samples and in other cancer cell lines.
Beschränkungen Nur für Forschungszwecke einsetzbar

Handhabung

Produktdetails anti-C-MYC Antikörper Target Details C-MYC Anwendungsinformationen Bilder zurück nach oben
Format Liquid
Konzentration 0.55-0.75 μg/μL
Lagerung -20 °C
Informationen zur Lagerung Storage of very dilute antibody solutions is not recommended.